Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Neurokinin-3 receptor antagonist

Fezolinetant

Brand names: Veoza

An oral neurokinin-3 (NK3) receptor antagonist used to treat moderate-to-severe vasomotor symptoms (hot flushes) associated with the menopause.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It blocks neurokinin B signalling at NK3 receptors on hypothalamic thermoregulatory neurons (KNDy neurons), helping to restore temperature control without using hormones.

Prescribing in practice

  • Hepatotoxicity has been reported, so liver function must be checked before starting and monitored during treatment, with the drug stopped if liver injury is suspected.
  • Contraindicated in known cirrhosis or significant hepatic impairment and avoided with strong CYP1A2 inhibitors.
  • It is a non-hormonal option, useful where oestrogen is unsuitable, but is not a contraceptive.

Monitoring

Monitor liver function before treatment and at intervals during therapy, advising patients to report symptoms of liver injury.

Counselling the patient

  • Attend for the recommended blood tests to check your liver.
  • Report nausea, vomiting, abdominal pain, dark urine or yellowing of the skin or eyes promptly.
  • This treats hot flushes but does not provide contraception.

Evidence & guidelines

Efficacy for menopausal vasomotor symptoms was demonstrated in the SKYLIGHT randomised controlled trial programme.

Reference: NICE TA982; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways